Projects
A randomized controlled trial of low-dose aspirin after initial anticoagulation to prevent the recurrence of venous thromboembolism - ASPIRE STUDY
Project Description
The ASPIRE study is an international multicentre, randomised, double-blind placebo controlled clinical trial designed to examine the efficacy and safety of low-dose aspirin (100 mg daily) to prevent recurrent deep vein thrombosis (DVT) or pulmonary embolism (PE) in patients with a first episode of unprovoked VTE who have completed initial treatment with heparin and warfarin. The primary outcome is recurrent symptomatic VTE or fatal PE. All patients with a first episode of unprovoked VTE who have received a recommended minimum duration of 3 months of warfarin therapy are potentially eligible for inclusion in this study.
a) Aim
The primary aim of this study is to determine whether low-dose aspirin is superior to placebo for the prevention of recurrent symptomatic VTE in patients with a first-ever episode of unprovoked VTE initially treated with standard anticoagulation (heparin and warfarin or effective alternatives).
b) Publication status (Name & year): The New England Journal of Medicine, 2012
Timothy A. Brighton, John W. Eikelboom, Kristy Mann, Rebecca Mister, Alexander Gallus, Paul Ockelford, Harry Gibbs, Wendy Hague, Denis Xavier, Rafael Diaz, Adrienne Kirby, & John Simes Low-Dose Aspirin for Preventing Recurrent Venous Thromboembolism, NEJM 2012, 10.1056/NEJMoa1210384
c) Publication link
Project Duration
2012 - Ongoing
Project Lead
Dr. Prem Pais, Dr. Denis Xavier
Authors
Dr Denis Xavier
Project Status
completed
Project Type
Source of Funding: National Health and Medical Research Council, Australia